Time will tell, but with Merck, Catalent, and Mylan/Pfizer all having an active roll with UNVC, I think we will have a comparable pps with them.
We'll have the stigma of a cannabis company, and the clout of a big pharma company. Plus, the big names on our BOD will be more respected once we get the filings and get out of the sewer. We'll attract more investment minded traders instead of.....the crowd we have now.
It doesn't get any better than that. All imo.
We'll have the stigma of a cannabis company, and the clout of a big pharma company. Plus, the big names on our BOD will be more respected once we get the filings and get out of the sewer. We'll attract more investment minded traders instead of.....the crowd we have now.
It doesn't get any better than that. All imo.
2